Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825577 | 0.91 | PRKCA (0.48) | PRKCAMMP12NR1I2GHSRKCNH2 | |
| SCHEMBL4829893 | 0.87 | NR1I2 (0.53) | PRKCAMMP12NR1I2KCNH2SCN9A | |
| SCHEMBL4829981 | 0.84 | PRKCA (0.47) | PRKCAMMP12NR1I2KCNH2SCN9A | |
| SCHEMBL13791919 | 0.84 | PRKCA (0.45) | PRKCAMMP12NR1I2KCNH2SCN9A | |
| SCHEMBL5337213 | 0.82 | NR1I2 (0.48) | PRKCAMMP12NR1I2SCN9ACNR2 | |
| SCHEMBL4140477 | 0.81 | NR1I2 (0.35) | PRKCAMMP12NR1I2GHSRKCNH2 | |
| SCHEMBL14253884 | 0.81 | PRKCA (0.43) | PRKCAMMP12NR1I2KCNH2SCN9A | |
| SCHEMBL3565283 | 0.81 | PRKCA (0.46) | PRKCAMMP12NR1I2KCNH2SCN9A | |
| SCHEMBL13941052 | 0.80 | PRKCA (0.46) | PRKCAMMP12NR1I2KCNH2SCN9A | |
| SCHEMBL3572572 | 0.80 | PRKCA (0.46) | PRKCAMMP12NR1I2KCNH2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | PRKCA 3479/4885MMP12 3512/4885NR1I2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.